News | October 29, 2025
Novartis completes acquisition of Tourmaline Bio
Tourmaline is now an indirect wholly owned subsidiary of Novartis
Tourmaline is now an indirect wholly owned subsidiary of Novartis
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
The event will be attended by 35,000+ industry professionals
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Subscribe To Our Newsletter & Stay Updated
